Web  accessibility  for the disabled Home Contact Us Email Us Shopping Cart
AAFA
AAFA Education Advocacy Research
  
AAFA Home Page
ASTHMA ALLERGIES AAFA
AAFA
 
AAFA
AAFA
AAFA
AAFA
You Can Help!
Certification Program
Educational Resources
Ask the Allergist
Find a Chapter
Find a Support Group
Health Professionals
En Español
Newsroom
Contact AAFA
Login


Asthma and Allergy
Foundation of America
1-800-7-ASTHMA
info@aafa.org
AAFA
Research

FDA Approved Drugs » 2012
Medical Areas: Immunology | Family Medicine | Infections and Infectious Diseases

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Gilead
Approval Status: Approved August 2012
Treatment Area: HIV-1 infection

General Information

Stribild is a once daily, fixed-dose single-tablet regimen of four drugs. Three of the four medications are active against HIV: the integrase inhibitor elvitegravir and the nucleotide/nucleoside reverse transcriptase inhibitors Viread (tenofovir) and Emtriva (emtricitabine). The fourth medication is cobicistat, a drug that has no activity against HIV, but is needed to boost the blood levels and effectiveness of elvitegravir.

Stribild is specifically indicated as a complete regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve.

Stribild is supplied as a tablet containing 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate. It is designed for oral administration. The recommended dose of Stribild is one tablet taken orally once daily with food.

Clinical Results

FDA Approval
The FDA approval of Stribild was based on 48 week data from two randomized, double-blind, active-controlled trials, Study 102 and Study 103, in treatment-naive, HIV-1 infected subjects (N=1408). In Study 102, subjects were randomized to receive either Stribild once daily or Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir DF 300 mg) once daily. In Study 103, subjects were randomized to receive either Stribild once daily or atazanavir 300 mg + ritonavir 100 mg (ATV+RTV) + Truvada (emtricitabine 200 mg/tenofovir DF 300 mg) once daily. In both studies, subjects were stratified by baseline HIV-1 RNA. The primary endpoint was Virologic Success (HIV-1 RNA < 50 copies/mL) at 48 weeks.
Study 102: Virologic success was reached by 88% in the Stribild arm and 84% in the Atripla arm. In Study 102, the mean increase from baseline in CD4+ cell count at Week 48 was 230 cells per mm3 in the Stribild-treated subjects and 193 cells per mm3 in the Atripla-treated subjects.
Study 103: Virologic success was reached by 90% in the Stribild arm and 87% in the ATV + RTV + Truvada arm. In Study 103, the mean increase from baseline in CD4+ cell count at Week 48 was 202 cells per mm3 in the Stribild-treated subjects and 201 cells per mm3 in the ATV + RTV + Truvada-treated subjects.

Side Effects

Adverse events associated with the use of Stribild may include, but are not limited to, the following:

  • nausea
  • diarrhea

Mechanism of Action

Stribild is a once daily, fixed-dose single-tablet regimen of four drugs: elvitegravir (an HIV-1 integrase strand transfer inhibitor), cobicistat (a mechanism-based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family), emtricitabine (a synthetic nucleoside analog of cytidine) and tenofovir disoproxil fumarate (an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate).

Literature References

Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012 Jun 30;379(9835):2439-48

DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012 Jun 30;379(9835):2429-38

Additional Information

For additional information regarding Stribild or HIV, please visit the Stribild web page.

 
Privacy Policy Home Contact Us Asthma Allergies Food Allergies Donate

 

Ask the allergist Shop Our Catalog Donate to AAFA